CAS: 34080-08-5; Protopanaxatriol

上下游产品

ginsenoside Rf 1ginsenoside Rh13β,6α,12β,25-tetrahydroxy-(20S,24S)-epoxy-dammarane (20S,24R)-epoxydammarane-3β,6α,12β,25-tetrol

📜人参皂苷rf置于aspergillus Niger β-Glucosidase,水体系中,化学反应 16.0H,以90.4%的收率获得产物原人参三醇
参考文献:黑曲霉将稀有的人参皂苷rf微生物转化为20(S)-原托泊那三醇.
标题:黑曲霉将稀有的人参皂苷rf微生物转化为20(S)-原托泊那三醇.
摘要:在这项研究中,稀有的人参皂苷rf被来自黑曲霉的糖苷酶转化为20(S)-原人参三醇(ppt(S)).通过投资反应条件,获得了最佳条件,如下:Ph 5.0,温度55°C,底物浓度1.25 Mmol / L.在最佳条件下,由1.25μmolrf制备的ppt(S)(1.13 Micromol)显示出较高的收率(90.4%).通过反相HPLC分析酶促反应,表明转化途径:Rf-> Rh1(S)-> Ppt(S).
DOI:10.1271/bbb.90596

专利信息

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:WO-2011107023-A1
优先权日:2010-03-05
标题:Compounds for preventing and treating disorders of metabolism and uses thereof
发明人：SONG BAOLIANG; TANG JINGJIE; LI JIAGUI; LI PEISHAN; QI WEI
权利人:SHANGHAI INST BIOL SCIENCES; SONG BAOLIANG; TANG JINGJIE; LI JIAGUI; LI PEISHAN; QI WEI
摘要:The present invention provides compounds and uses thereof for preventing and treating metabolic disorders such as hyperlipemia, atherosclerosis, type II diabetes and so on. The present invention firstly discloses new inhibitors by SREBP route which can specifically inhibit the synthesis of lipid such as cholesterol, fatty acid, triglyceride and so on by inhibiting the SREBP route and can reduce the level of lipid. So the present invention can provide a new method for preventing and treating metabolic disorders such as adiposity, atherosclerosis, type II diabetes and so on.

专利号:US-2006014729-A1
优先权日:2004-07-16
标 题 :Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production
发明人：LANDRY DONALD W; KIM TAE-WAN; DENG SHIXIAN
权利人:LANDRY DONALD W; KIM TAE-WAN; DENG SHIXIAN
摘要:The present invention provides novel dammarane compounds, compositions (e.g., pharmaceutical compositions) comprising the dammarane compounds, and methods for the synthesis of these dammarane compounds. Additionally, the present invention provides methods for inhibiting beta-amyloid peptide production and methods for treating or preventing a pathological condition, particularly, neurodegeneration diseases (e.g., Alzheimer's disease), using these dammarane compounds.